αCD33-28ζ-CAR T cells

αCD33-28ζ-CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to treat acute myeloid leukemia (AML) by targeting the CD33 antigen, which is widely expressed on the surface of myeloid leukemia blasts. This second-generation CAR construct incorporates a CD28 costimulatory domain and a CD3ζ signaling domain to drive T-cell activation and proliferation upon antigen engagement. Developed by researchers at the University Hospital, LMU Munich, the therapy is being further optimized through chemokine receptor engineering—specifically co-expressing CCR2 or CXCR2—to enhance the migration and homing of the CAR T cells to the bone marrow niche, where AML cells predominantly reside. While these modifications improve targeted migration toward ligands like CCL2 and CXCL8, ongoing research is investigating the mechanisms behind observed reductions in cytotoxic efficacy at high effector-to-target ratios to refine the therapeutic potential of this approach.

Other names

CD33-28z CAR-T cellsCD-33-28z CAR-T cellsCD 33-28z CAR-T cellsanti-CD33-28ζ CAR T cells